AVI BioPharma Announces Third Quarter 2010 Financial Results and Corporate Update Conference Call
November 02 2010 - 1:00PM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, will report third quarter 2010 financial results
after the NASDAQ Global Market closes on Tuesday, November 9, 2010.
Subsequently, at 5:00 p.m. Eastern time (2:00 p.m. Pacific time),
J. David Boyle II, AVI's Interim President and Chief Executive
Officer, and Chief Financial Officer, and Stephen B. Shrewsbury,
AVI's Senior Vice President and Chief Medical Officer, will host a
conference call to discuss third quarter 2010 financial results and
to provide a corporate update.
The conference call may be accessed by dialing 800.573.4842 for
domestic callers and 617.224.4327 for international callers. The
passcode for the call is 29591329 and please specify to the
operator that you would like to join the "AVI BioPharma third
quarter 2010 earnings call." The conference call will be webcast
live under the events section of AVI's website at www.avibio.com,
and will be archived there following the call. Please connect to
AVI's website several minutes prior to the start of the broadcast
to ensure adequate time for any software download that may be
necessary.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
novel RNA-based therapeutics for rare and infectious diseases, as
well as other select disease targets. Applying pioneering
technologies developed and optimized by AVI, the Company is able to
target a broad range of diseases and disorders through distinct
RNA-based mechanisms of action. Unlike other RNA-based approaches,
AVI's technologies can be used to directly target both messenger
RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either
down-regulate (inhibit) or up-regulate (promote) the expression of
targeted genes or proteins. By leveraging our highly differentiated
RNA antisense-based technology platform, AVI has built a pipeline
of potentially transformative therapeutic agents, including one in
the clinical development stage for the treatment of Duchenne
muscular dystrophy. For more information, visit www.avibio.com.
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024